Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other Non-Current Assets: 2010-2024

Historic Other Non-Current Assets for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to $5.7 million.

  • Anika Therapeutics' Other Non-Current Assets fell 51.31% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 51.31%. This contributed to the annual value of $5.7 million for FY2024, which is 84.42% down from last year.
  • Latest data reveals that Anika Therapeutics reported Other Non-Current Assets of $5.7 million as of FY2024, which was down 84.42% from $36.3 million recorded in FY2023.
  • Anika Therapeutics' 5-year Other Non-Current Assets high stood at $36.3 million for FY2023, and its period low was $5.7 million during FY2024.
  • In the last 3 years, Anika Therapeutics' Other Non-Current Assets had a median value of $17.2 million in 2022 and averaged $19.7 million.
  • Per our database at Business Quant, Anika Therapeutics' Other Non-Current Assets surged by 110.84% in 2023 and then crashed by 84.42% in 2024.
  • Anika Therapeutics' Other Non-Current Assets (Yearly) stood at $15.4 million in 2020, then skyrocketed by 31.55% to $20.3 million in 2021, then declined by 15.11% to $17.2 million in 2022, then surged by 110.84% to $36.3 million in 2023, then slumped by 84.42% to $5.7 million in 2024.